AnPro: Athermal Nerve-sparing During Robotic-assisted Radical Prostatectomy Using a Hemostatic Matrix.
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the use of a hemostatic gelatine-thrombin matrix during athermal nerve-sparing prostate resection compared to conventional hemostasis using electrocautery in patients with localized prostate cancer and to investigate effects on postoperative erectile function and continence.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: gelatine-thrombin matrix Nerves-paring during robotic-assisted laparoscopic prostatectomy is conducted without mono- or bipolar electrocautery and clipping by using a hemostatic gelatine-thrombin matrix. |
Procedure: Application of a hemostatic gelatin-thrombin matrix
Hemostatic gelatin-thrombin matrix is used for hemostasis during nerve-sparing dissection of the prostate.
|
Sham Comparator: Control Nerve-sparing during robotic-assisted radical prostatectomy is conducted with the use of mono- and bipolar electrocautery and surgical clipping. |
Procedure: Use of mono- and bipolar electrocautery and surgical clips
Mono- and bipolar electrocautery and surgical clips are used for hemostasis during nerve-sparing dissection of the prostate.
|
Outcome Measures
Primary Outcome Measures
- Postoperative erectile function [12 months]
Postoperative erectile function compared to preoperative status assessed validated questionnaires.
Secondary Outcome Measures
- Postoperative continence [12 months]
Postoperative continence compared to preoperative status assessed by validated questionnaires.
- Intraoperative bloodloss [During surgery]
Amount of blood collected in the suction during surgery.
- Intra- and postoperative complications [Perioperative period]
Intra- and postoperative complications associated to the study´s intervention.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient age >18
-
Histologically proven prostate cancer ( Gleason <8; PSA<10ng/ml)
-
Disease confined to prostate in clinical examination
-
Preoperative IEEF-5-Score>20
-
Patient is able to give informed consent
Exclusion Criteria:
-
ASA IV-V
-
Prior extensive abdominal surgery
-
Signs for metastatic disease
-
Known allergy against bovine material
-
Patient is unable to give informed consent
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Johann Wolfgang Goethe University Hospital | Frankfurt/M. | Germany | 60590 |
Sponsors and Collaborators
- Johann Wolfgang Goethe University Hospital
Investigators
- Principal Investigator: Axel Haferkamp, Prof., Johann Wolfgang Goethe University Hospitals, Germany
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AnPro